Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMISE-C19: Comparative Effectiveness of Monoclonal Antibodies for COVID-19
NCT04790786Phase 4Terminated
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 4 trial of bamlanivimab, casirivimab, imdevimab, etesevimab, sotrovimab in coronavirus disease 2019 (COVID-19). Started Mar 2021; status: terminated.
02
Drugs
bamlanivimabcasirivimabimdevimabetesevimabsotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04790786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04790786.